Phibro Animal Health PAHC Acquisition Related Cost Of Goods Sold

Discontinued — last reported Q2 '24

Other financials

Revenue$383.5M+10.3%

Gross profit$125.7M+20.2%

Operating income$44.7M+33.2%

Net income$24.0M+15.1%

EPS (diluted)$0.59+15.7%

Cash & equivalents$54.9M-9.0%

Total debt$32.3M+27.8%

Total equity$361.8M+36.0%

Total assets$1.4B+9.7%

Operating cash flow$16.2M-62.4%

CapEx$15.3M+97.7%

Free cash flow$890.0K-97.5%

Market cap$1.29B+33.4%

Enterprise value$1.27B+36.0%

P/E13.6×-16.9×

P/S0.9×0.0×

Gross margin32.5%+0.9pp

Operating margin12%+4.0pp

Net margin6.3%+3.7pp

FCF margin0.9%-3.3pp

Return on equity30.3%+18.5pp

Debt / equity0.1×0.0×

Current ratio3.2×+0.3×

Reported directly by Phibro Animal Health in its filing.

Tagged under the XBRL concept pahc:AcquisitionRelatedCostOfGoodsSold.

The official record: Phibro Animal Health’s 10-Q, filed February 7, 2024, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Phibro Animal Health's acquisition related cost of goods sold?: Phibro Animal Health (PAHC) reported acquisition related cost of goods sold of $310K in Q4 2023.